Clinical delineation, sex differences, and genotype-phenotype correlation in pathogenic KDM6A variants causing X-linked Kabuki syndrome type 2. by Faundes, V et al.
ARTICLE
Clinical delineation, sex differences, and genotype–phenotype
correlation in pathogenic KDM6A variants causing X-linked
Kabuki syndrome type 2
Víctor Faundes1,2, Stephanie Goh3, Rhoda Akilapa4, Heidre Bezuidenhout5,6, Hans T. Bjornsson7,8, Lisa Bradley9, Angela F. Brady4,
Elise Brischoux-Boucher10, Han Brunner11, Saskia Bulk12, Natalie Canham4,13, Declan Cody9, Maria Lisa Dentici14, Maria Cristina Digilio14,
Frances Elmslie15, Andrew E. Fry16, Harinder Gill9, Jane Hurst17, Diana Johnson18, Sophie Julia19, Katherine Lachlan20,
Robert Roger Lebel21, Melissa Byler21, Eric Gershon22, Edmond Lemire23, Maria Gnazzo24, Francesca Romana Lepri24,
Antonia Marchese25, Meriel McEntagart15, Julie McGaughran26, Seiji Mizuno27, Nobuhiko Okamoto28,29, Claudine Rieubland30,
Jonathan Rodgers26, Erina Sasaki9, Emmanuel Scalais31, Ingrid Scurr32, Mohnish Suri33, Ineke van der Burgt34, Naomichi Matsumoto35,
Noriko Miyake35, Valérie Benoit36, Damien Lederer36 and Siddharth Banka 1,37✉
PURPOSE: The variant spectrum and the phenotype of X-linked Kabuki syndrome type 2 (KS2) are poorly understood.
METHODS: Genetic and clinical details of new and published individuals with pathogenic KDM6A variants were compiled and
analyzed.
RESULTS: Sixty-one distinct pathogenic KDM6A variants (50 truncating, 11 missense) from 80 patients (34 males, 46 females) were
identified. Missense variants clustered in the TRP 2, 3, 7 and Jmj-C domains. Truncating variants were significantly more likely to be
de novo. Thirteen individuals had maternally inherited variants and one had a paternally inherited variant. Neonatal feeding
difficulties, hypoglycemia, postnatal growth retardation, poor weight gain, motor delay, intellectual disability (ID), microcephaly,
congenital heart anomalies, palate defects, renal malformations, strabismus, hearing loss, recurrent infections, hyperinsulinism,
seizures, joint hypermobility, and gastroesophageal reflux were frequent clinical findings. Facial features of over a third of patients
were not typical for KS. Males were significantly more likely to be born prematurely, have shorter stature, and severe developmental
delay/ID.
CONCLUSION: We expand the KDM6A variant spectrum and delineate the KS2 phenotype. We demonstrate that the variability of
the KS2 phenotypic depends on sex and the variant type. We also highlight the overlaps and differences between the phenotypes
of KS2 and KS1.
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INTRODUCTION
Kabuki syndrome (KS, MIM 147920 and MIM 300867) is one of the
commonest congenital disorders caused by variants in genes
encoding histone lysine methylases and demethylases.1 It is
characterized by a distinctive facies (long palpebral fissures with
eversion of the lateral third of the lower eyelid; arched and broad
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eyebrows with the lateral third displaying notching or sparseness;
large, prominent, or cupped ears; and short columella with
depressed nasal tip), developmental delay and/or intellectual
disability (ID), and several structural (e.g., congenital heart defects,
genitourinary malformations) and functional anomalies (e.g.,
increased susceptibility to infections, endocrine disorders, deaf-
ness).2 The majority of patients with KS have loss-of-function (LoF),
mostly de novo, variants in KMT2D (formerly known as MLL2 and
ALR) (KS1, MIM 147920).3,4 KMT2D is located on chromosome 12,
and encodes lysine (K)-specific methyltransferase 2D, which
catalyzes the trimethylation of the lysine 4 on histone 3 (H3K4),
promoting the expression of its target genes.5
In two girls and a boy with KS-like features, Lederer et al.6
identified de novo X-chromosome deletions that encompassed
KDM6A (formerly known as UTX) (KS2, MIM 300867). Miyake et al.7
and Banka et al.8 subsequently identified pathogenic point
variants in KDM6A by targeted sequencing in cohorts of patients
clinically suspected to have KS and showed that KDM6A variants
account for ~5% cases of KS. KDM6A partially escapes X-
inactivation.6,9 The canonical transcript (GenBank NM_021140.3;
Ensembl ENST00000377967.8) has 29 exons and encodes a H3K27
demethylase of 1,401 amino acids (UniProtKB entry O15550). The
Jumonji-C (Jmj-C) domain is the catalytic lysine demethylase
domain, which is situated toward the C-terminus of the protein.10
Toward its N-terminus, the protein includes eight tetratricopeptide
repeats (TPR) that may contribute indirectly to substrate binding,
but their precise function is unknown.
Most published patients with KDM6A variants have been
primarily ascertained based on phenotype as part of short case
series or single case reports.7,8,11–16 It is known that the phenotype
of patients with KS2 can be atypical for KS.8,17 Application of
next-generation sequencing (NGS)–based diagnostics is enabling
identification of patients with KDM6A variants and atypical
phenotypes.17 Accurate clinical correlation of KDM6A variants in
absence of typical phenotype can be challenging (especially for
inherited missense variants) because the KDM6A variant and clinical
spectra are not well defined. Also, lack of genotype–phenotype
correlation studies makes estimation of prognosis challenging. Here
we present a large case series of patients with KDM6A variants that
helps broaden the variant spectrum, delineates the range of the
associated clinical features, enables comparison of phenotypes of




New patients. Procedures were in accordance with local ethical
standards. Individuals with rare KDM6A variants were mainly identified
via the Manchester Centre for Genomic Medicine, UK (Research Ethics
Committee Approval [RECA] 02/CM/238), Centre de Génétique Humaine,
Institut de Pathologie et de Génétique, Belgium (RECA 050612), Epigenetic
and Chromatin Clinic at Johns Hopkins Hospital, USA (IRB approval:
NA_00079185), and the Deciphering Developmental Disorders (DDD)
study (RECAs 10/H0305/83 and GEN/284/12).18
Previously reported individuals. All articles indexed in PubMed between 1
January 2012 (year in which in KDM6A variants were first associated with
KS6) and 31 March 2019 were retrieved using the following terms “KDM6A
NOT(cancer)” OR “Kabuki NOT(Kabuki[Author])” OR “Kabuki make-up,” OR
“Niikawa-Kuroki.” Articles on KS1 or papers that did not provide the
phenotype of affected individuals were excluded following title and
abstract review. Full texts of the remaining articles were reviewed. The
criteria for including published patients in the present study were (1)
availability of clinical details, (2) unambiguous description of the KDM6A
variant, and (3) not duplicated from any previous report. Exclusion criteria
were (1) patients with copy-number losses that encompassed additional
known developmental disorder related genes, and (2) patients with
additional known genetic developmental disorders.
Variant analysis. All detected point variants were harmonized according
to the canonical KDM6A transcript NM_021140.3 using MutationTaster2
(http://www.mutationtaster.org/). InterVar (http://wintervar.wglab.org/)
was used to apply the 2015 American College of Medical Genetics and
Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines for
variant interpretation.19 Protein altering variants (PAVs) were analyzed by
the Variant Effect Predictor (http://grch37.ensembl.org/Homo_sapiens/
Tools/VEP) to obtain minor allele frequencies (MAFs) in controls, exon
location, in silico predictions, previous reports, and evolutionary conserva-
tion. Alamut® Visual 2.11 (Interactive Biosoftware, France) and UniProtKB
(https://www.uniprot.org/uniprot/O15550) were used for exon-skipping
analyses and determining affected domains, respectively. PAVs with
decreased in vitro demethylation were obtained from the work of
Shpargel et al.20 To analyze copy-number variants (CNVs) encompassing
KDM6A, the University of California–Santa Cruz (UCSC) Genome Browser
(GRCh37) was used.
Data collection
Clinical data were collected on individuals with pathogenic or likely
pathogenic (just pathogenic hereafter) KDM6A variants. The clinical
proforma was completed by recruiting clinicians for new patients. V.F.
(the first author of the present study) completed the proforma for
previously published patients.
Statistical analyses
For calculation of frequencies of individual features, we excluded
individuals for whom that feature was coded as “UNKNOWN” (which
includes instances where presence or absence of a particular feature was
not clearly documented or where a feature may not be applicable due to
the individual’s sex or age) in the clinical proforma (Supplementary
Table S1). Absolute and relative frequencies (expressed as n[%]) were used
for describing categorical variables, whereas medians (m), interquartile
ranges (IQR) and minimum (min) and maximum (max) were used for
describing continuous variables. Chi-square/Fisher’s exact and
Wilcoxon–Mann–Whitney test was applied to study categorical and
continuous variables respectively. Two-tailed/adjusted p value <0.05 was
considered as significant for all statistical analyses, which were carried out
using the IBM© SPSS© Version 25 software.
RESULTS
Ascertainment
We identified 36 new patients (18 males/18 females) with hetero/
hemizygous KDM6A variants (Supplementary Table S1). We also
identified 49 patients (19 males and 30 females) with KDM6A
variants from 17 peer-reviewed articles (Supplementary Figure S1
and Supplementary Table S1).
Variants
In total, we compiled 66 distinct KDM6A variants from these 85
patients (37 males, 48 females) from 78 families. This included 50
PTVs in 62 individuals (26 males, 36 females) from 59 families
(Fig. 1a, b) and 16 PAVs in 23 individuals (11 males, 12 females)
(Fig. 1c) from 19 families.
All the PTVs were classified as pathogenic. We identified 15
novel PTVs. Fifteen of the 50 PTVs (30%) were nonsense, 14 (28%)
affected canonical splice sites, 12 (24%) were frameshift, 8 (16%)
were gross deletions, and 1 (2%) resulted from a gene-disrupting
chromosome translocation (Fig. 1a, b, and Supplementary
Figure S2A). In 42 patients (13 males, 29 females) the KDM6A
PTVs had occurred de novo, whereas 6 patients (5 males, 1 female)
had inherited their variants from mothers. The inheritance of
14 PTVs (8 males, 6 females) was unknown (Supplementary
Figure S2B).
Of 16 PAVs, 12 were classed as pathogenic or likely pathogenic,
3 were classed as variants of uncertain significance (VUS), and 1
was classed as likely benign (Supplementary Table S2 and
Supplementary Figure S2D). Patients with VUS or likely benign
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variants (five patients in total) were excluded from subsequent
analyses. Thirteen of the 16 PAVs (81.3%) were missense, 2 (12.5%)
were in-frame deletions, and 1 (6.2%) was an indel (Fig. 1c
and Supplementary Figure S2A). Eight PAVs (2 males, 6 females)
had occurred de novo. Ten patients (7 males, 3 females) had
inherited their PAVs from their mothers (in one case mother is
mosaic for p.Arg1255Trp) and one female had inherited her p.
Ala149Thr KDM6A PAV from her father. Inheritance of 4 PAVs
(2 males, 2 females) was unknown (Supplementary Figure S2B).
Clinical delineation of KS2
In total, we analyzed clinical findings from 80 individuals with
pathogenic or likely pathogenic KDM6A variants (Table 1). In this
cohort 57.5% (n= 46) were females, and the median age at last
examination was 7 years (min= 0.21, max= 37). The youngest
male patient was 2.5 months old and the oldest male patient was
37 years old. The youngest female patient was 3.5 months old and
the oldest female patient was 37 years old.
Feeding difficulty was the most frequent neonatal finding.
Hypoglycemic was described in 56.4% of neonates (Table 1). The
median weight at last examination was −1.43 SD (min=−4, max
= 2.28), the median height was −2 SD (min=−7, max= 2.3), and
the median head circumference (HC) was −2.34 SD (min=−5.33,
max= 2.45). Motor delay was described in 95% of individuals.
Overall, 73.8% of patients were reported to have achieved
independent walking (Table 1), and 79.4% of patients older than
3 years of age (n= 34) had achieved independent walking
(Supplementary Table S1). Speech delay was reported in 91.5%
of individuals and 71.4% had achieved speech. ID was reported in
93% of individuals with more than half being classified as having
severe ID. Congenital malformations affecting the cardiovascular
system were most frequent, followed by palatal and renal
malformations. Strabismus and hearing loss were the most
frequent problem affecting the sensory system. Recurrent infec-
tions, hyperinsulinism, seizures, joint hypermobility, and gastro-
esophageal reflux were some of the other most significant and
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Fig. 1 Spectrum of pathogenic KDM6A variants. (a) Protein-truncating variants (PTVs) described in this study. The x-axis shows the
exon–intron locations and the y-axis shows the number of variants detected. Novel PTVs are underlined. (b) Deletions described in this study.
The x-axis shows the exons affected. Novel deletions are underlined. (c) Protein-altering variants (PAVs) described in this study. The x-axis
shows the protein location and the y-axis shows the number of variants detected. Novel PAVs are underlined. (d) Control variants seen in
gnomAD, PTVs at the top and missense variants at the bottom. The x-axis shows the protein location and y-axis shows the minor allele
frequencies of missense variants. MAF minor allele frequency.
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patients had typical KS facial features, as defined by the diagnostic
criteria2 (Table 1, Fig. 2).
Sex differences in KS2
Next we compared the frequencies of clinical features between
male and female patients (Table 2) (Fig. 3a, b). Where full
Table 1. Clinical findings and their frequencies or distributions
across 80 new and published cases of Kabuki syndrome type 2.
Clinical findinga Frequency or distribution
Sex (males/females, n[%]) (n= 80) 34 (42.5)/46 (57.5)
Age at last examination (years, m[IQR])
(n= 57)
7 (3.25; 13)




Weight SD (m[IQR]) (n= 43) −1.43 (−2.65; 0)
Height SD (m[IQR]) (n= 46) −2 (−2.82; −1.16)
HC SD (m[IQR]) (n= 43) −2.34 (−3; −0.61)
Antenatal and neonatal features
Abnormal pregnancy findings (n[%])
(n= 27)
10 (37)
Gestation duration (weeks, m[IQR])
(n= 45)
38 (36; 39)
Birth weight SD (m[IQR]) (n= 44) 0.01 (−1.19; 0.69)
Birth length SD (m[IQR]) (n= 18) −0.64 (−1.31; 0.83)
Birth HC SD (m[IQR]) (n= 20) −0.15 (−1.25; 0.31)
Neonatal hypotonia (n[%]) (n= 44) 35 (79.5)






Neurological and developmental features
Motor delay (n[%]) (n= 61) 58 (95.1)
Independent walking (n[%]) (n= 42) 31 (73.8)
Age at which independent walking
achieved (months, m[IQR]) (n= 27)
19 (17; 30)
Speech delay (n[%]) (n= 59) 54 (91.5)
Developed speech (n[%]) (n= 42) 30 (71.4)
First words (months, m[IQR]) (n= 20) 24.5 (20; 36)
Intellectual disability (n[%]) (n= 57) 53 (93)
Intellectual disability severity (n= 39)
Mild (n[%]) 9 (23.1)
Moderate (n[%]) 9 (23.1)
Severe (n[%]) 21 (53.8)
Behavioral problems (n[%]) (n= 41) 24 (58.5)
Seizures history (n[%]) (n= 47) 17 (36.2)
Hypotonia (n[%]) (n= 53) 34 (64.2)
CNS anomalies (n[%]) (n= 28) 17 (60.7)
Ventriculomegaly (n[%]) 6 (21.4)
Delayed CNS myelination (n[%]) 3 (10.7)
Other (n[%]) 10 (35.7)
Ectodermal anomalies (n[%]) (n= 48) 45 (93.8)
Fetal fingertip pads (n[%]) 35 (72.9)
Hypertrichosis (n[%]) 11 (22.9)
Nail anomalies (n[%]) 5 (10.4)




Brachy/clinodactyly (n[%]) 24 (43.6)
Joint hypermobility (n[%]) 23 (41.8)
Hip problems (n[%]) 14 (25.5)
Other (n[%]) 15 (27.33)
Table 1 continued




Feeding difficulties requiring support
(n[%])
33 (61.1)
Gastroesophageal reflux (n[%]) 15 (27.8)
Chronic diarrhea (n[%]) 3 (5.6)
Recurrent vomiting (n[%]) 1 (1.9)
Palate anomalies (n[%]) (n= 67) 43 (64.2)
High/narrow palate (n[%]) 38 (56.7)
Cleft lip/palate (n[%]) 8 (11.9)
Velopharyngeal insufficiency (n[%]) 3 (4.5)
Dental anomalies (n[%]) (n= 45) 27 (60)
Hypodontia (n[%]) 10 (22.2)
Malocclusion (n[%]) 7 (15.6)
Neonatal teeth (n[%]) 7 (15.6)
Other (n[%]) 12 (26.7)
Ophthalmological problems (n= 48) 28 (58.3)
Strabismus (n[%]) 15 (31.3)
Nystagmus (n[%]) 5 (10.4)




Recurrent infections (n[%]) 22 (42.3)
Eczema (n[%]) 4 (7.7)
Other (n[%]) 4 (7.7)
Cardiovascular anomalies (n[%]) (n= 63) 31 (49.2)
Septal defects (n[%]) 15 (23.8)
Valvular anomalies (n[%]) 11 (17.5)
Aorta anomalies (n[%]) 10 (15.9)
Other (n[%]) 13 (20.6)
Endocrine anomalies (n[%]) (n= 47) 18 (38.3)
Hyperinsulinism (n[%]) 13 (27.7)
Breast anomaliesd (n[%]) 5 (10.6)
Other (n[%]) 2 (4.3)
Hearing loss (n[%]) (n= 26) 8 (30.8)
Genitourinary anomalies (n[%]) (n= 53) 14 (26.4)
Horseshoe kidneys (n[%]) 4 (7.5)
Vesicoureteric reflux (n[%]) 2 (3.8)
Other (n[%]) 12 (22.6)
The table is arranged according to the highest to lowest frequency of
features in individual system.
CNS central nervous system, HC head circumference, IQR interquartile
range, m median.
aThe number of responders are detailed for every feature, and their
frequencies/distributions were calculated according to that number.
bAs defined by the Kabuki Syndrome Medical Advisory Board.
cAt last examination.
dIt includes gynecomastia and premature thelarche.
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inheritance information was available, de novo variants were
found to be significantly more likely in affected females (females
= 92.1% vs. males= 62.5%; p= 0.007) (Table 2). Affected males
were born significantly earlier, and had shorter birth lengths in
comparison with female patients (Table 2) (Fig. 3). Males were
significantly shorter in stature at the last examination (Table 2)
(Fig. 3). Fewer males could walk independently or developed
speech (Table 2). Males also significantly more frequently had
severe ID (Table 2), (Fig. 3). Males displayed a significantly higher
frequency of gastrointestinal problems when compared with
females (males= 88% vs. females= 62.1%; p= 0.03) (Table 2)
(Fig. 3).
Genotype–phenotype correlation in KS2
Next we compared the frequencies of clinical features between
patients with PTVs and PAVs (Table 2) (Fig. 3a, b). PTVs were found
to be significantly more likely to have occurred de novo (PTVs=
87.5% vs. PAVs= 57.1%; p= 0.02) (Table 2). Age of last medical
examination of individuals with PTVs was significantly earlier in
comparison with individuals with PAVs (Table 2). Individuals with
PAVs had shorter birth lengths in comparison with individuals
with PTVs (Table 2) (Fig. 3a, b). There was no association between
sex of the affected individuals and the type of variants (PAVs in
males= 23.5%; PAVs in females= 21.7%; PTVs in males= 76.5%;
PTVs in females= 78.3%; p= 0.85).
DISCUSSION
To date, this is the largest study of individuals with pathogenic
KDM6A variants, which allows delineation of the variant spectrum,
the clinical features of KS2, and allows us to determine the sex
differences and genotype–phenotype correlations. The age range
of our cohort and the sex distribution suggests that these data are
likely to be representative of most patients seen in clinics.
Spectrum of pathogenic KDM6A variants
This study substantially expands the known spectrum of
pathogenic KDM6A variants; 87.5% (n= 70) of the individuals in
this study have KDM6A point variants (Fig. 1, Supplementary
Figure 2A, Supplementary Table S1), which is in contrast with the
initial description of large deletions.6 However, this is reflective of
our recruitment criteria that resulted in exclusion of large CNVs.
We found that 72.9% (n= 62) individuals had KDM6A PTVs
(Fig. 1 and Supplementary Figure 2A) (Supplementary Table S1),
which is similar to our observations in several other disorders
caused by variants in histone lysine methylases and demethy-
lases.1 We found the KDM6A PTVs to be distributed throughout
the gene, from exon 1 to exon 27 in both male and female
cohorts.
Previously, only five distinct pathogenic KDM6A PAVs have been
published and our study substantially increases this number.
Pathogenic PAVs were mainly found to cluster in the TRP 2, TRP 3,
TRP 7 and Jmj-C domains of KDM6A (Fig. 1). However, the p.
(Ser1025Gly) and the p.(Lys1080_1083delinsGlySer) variants are
located outside any known domains.21 The p.(Arg1255Trp) variant,
located in the JmjC domain, was seen in two unrelated individuals,
and was proven to be de novo in one patient.17 The variants
c.445G>A (p.[Ala149Thr]), c.563A>G (p.[Lys188Arg]) and c.974G>C
(p.[Gly325Ala]) affect the nucleotides near the exon–intron
boundaries and could potentially affect normal splicing. We could
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Fig. 2 Facial phenotypes of patients with KDM6A variants are highly variable. Patients are grouped according to sex and type of variant.
Most patients have arched eyebrows, long palpebral fissures, some eversion of the lateral part of the lower eyelids, and bulbous or rounded
nasal tip. Unlike the classical gestalt of Kabuki syndrome, the eyebrows are interrupted in only some patients, and are thick in many (P4, 11, 60,
66, and 67) or thin and penciled occasionally (P1, 72). Lateral flaring of eyebrows is observed in some patients (P11, 67, 69, and 74). Ears are
not simple or as prominent as usually seen in patients with classic Kabuki syndrome. In several patients they appear relatively large and rather
fleshy. Prominent lower lips or pillowing of the lower lips was observed in some patients (P11, 21, 42, 44, 60, 67, and 74). Prominent forehead
was observed frequently. Patient 20 inherited the p.Ala149Thr variant form her father, who is similarly affected. PAV protein-altering variants,
PTV protein-truncating variants.
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not test effect of these variants on splicing as part of this study.
These results should facilitate interpretation of KDM6A variants
in clinics. In the future, functional analysis using DNA methylation
signatures22–25 or epigenetic reporter assays26 might be useful to
determine the significance of some PAVs. In future, systematic
comparison of KDM6A germline and somatic missense variants, as
recently performed for KMT2D, might also be possible.27
Inheritance of pathogenic KDM6A variants
Although a vast majority of pathogenic KDM6A variants
occurred de novo, we found 12 cases from 9 families with
inherited pathogenic variants. Seven (4 PTVs and 3 PAVs) were
inherited from similarly affected mothers. In other cases, the
phenotype information of the mother was not available. Notably,
where complete inheritance information was available, inherited
variants constituted variants of 59% males of our cohort and
42.9% of PAVs. These figures might be overestimated due to
inheritance information not being available in 25% of the cohort
(assuming that the parents who appeared unaffected are less
likely to be tested). However, our data clearly show that some
women with KS2 can have children. One affected boy inherited a
mosaic LoF KDM6A variant from his unaffected mother. Interest-
ingly, we also detected one pathogenic PAV p.(Ala149Thr)
inherited from a similarly affected father. Paternally inherited
pathogenic KDM6A variant has never been described previously.
Together these findings emphasize the importance of parental
testing in patients with pathogenic KDM6A variants and have
important implications in clinical practice and counseling.
Antenatal and neonatal phenotype of pathogenic KDM6A variants
Our data suggest that intrauterine growth retardation (IUGR) is the
most frequent significant prenatal finding in patients with
pathogenic KDM6A variants (Table 1 and Supplementary Table S1).
IUGR was present in 6.25% of patients in our total cohort and in
18.5% patients where prenatal information was available. Fewer
than 10% of patients with KS1 and/or clinically diagnosed KS have
IUGR.28 Interestingly 11 of 13 patients in our cohort known to have
been born prematurely (before 37 weeks of gestation) were males.
Birth length and HC in patients with pathogenic KDM6A variants
were observed to be in normal-to-low range. Males with
pathogenic KDM6A variants appear to have significantly smaller
birth lengths.
Growth and development in patients with pathogenic KDM6A
variants
Among patients with clinically diagnosed KS, 55–71% have short
stature and 25–32% have microcephaly.29–31 In our cohort of
patients with pathogenic KDM6A variants short stature was less
frequent (48%) and microcephaly was more frequent (54%)
(Supplementary Table S1). Comparisons of SDs of weights,
lengths/heights, and HCs at last examination against measure-
ments at birth, clearly reveal that the growth retardation in this
condition is mostly of postnatal origin. The distribution of height
SDs reveals a trend across the four groups (males with PTVs <
males with PAVs < females with PTVs < females with PAVs). Hence,
the sex and the type of variant should be considered in growth-
related prognosis and treatment of patients with KS2. Similar to
what is seen in KS1, 5/9 patients in our cohort with age of >15
years had a body mass index >25 kg/m2 (Table 1) suggesting a
tendency to be overweight or obese with age,32,33 that may have
important medical implications. Larger data sets from adults with
KS2 is required to enable correlation with sex and variant types.
Developmental delay and/or intellectual disability is reported in
over 84%30 patients with clinically diagnosed cases of KS. In our
cohort these phenotypes were found in 95% of patients (Table 1
Table 2. Significant associations between clinical features and sex or variant group.
Feature Association p valuea
Females Males
De novo variants (n[%]) 35 (92.1) 15 (62.5) 0.007
Gestation (weeks, m[IQR]) 39 (38; 39) 36 (35.3; 38.5) 0.003
Birth length SD (m[IQR]) −0.01 (−0.41; 1.24) −1.07 (−1.75; −0.53) 0.013
Height SD (m[IQR])a −1.2 (−2.67; −0.77) −2.18 (−3.76; −1.94) 0.005
Independent walking (n[%]) 21 (95.5) 10 (50) 0.001
Developed speech (n[%]) 20 (90.9) 10 (50) 0.003
ID severity 0.021
Mild (n[%]) 7 (33.3) 2 (11.1)
Moderate (n[%]) 7 (33.3) 2 (11.1)
Severe (n[%]) 7 (33.3) 14 (77.8)
Behavioral problems (n[%]) 18 (75) 6 (35.3) 0.011
Ectodermal anomalies (n[%]) 31 (100) 14 (82.4) 0.039
Gastrointestinal problems (n[%]) 18 (62.1) 22 (88) 0.03
PAV PTV
De novo variants (n[%]) 8 (57.1) 42 (87.5) 0.02
Age at last examination (years, m[IQR]) 12 (6.5; 14.08) 6.35 (1.94; 11.02) 0.043
Birth length SD (m[IQR]) −1.56 (−1.86; −0.9) −0.29 (−0.98; 0.93) 0.034
ID intellectual disability, IQR interquartile range, m median, PAV protein-altering variant, PTV protein-truncating variant.
aAt last examination.
V. Faundes et al.
6
Genetics in Medicine _#####################_
and Supplementary Table S1). Differences in the ascertainment
criteria of historical studies of KS make comparisons with our data
challenging. However, it is clear that the frequency and the
severity of neurodevelopmental problems in males with patho-
genic KDM6A variants are significantly greater. Males have
significantly lower levels of independent walking and speech. Of
note, there was no significant difference in the ages at last
examination of male and female patients in this cohort (p= 0.924).
Notably, the developmental phenotype of females was much
more variable than in males. This variability in presentation could
be due to differences in X-chromosome inactivation in females.
However, systematic X-chromosome inactivation studies will be
needed to confirm this. This is particularly interesting because
KDM6A is known to partially escape X-inactivation.6
Patients with PTVs tended to have more intellectual disability
(97.6% versus 80%, p= 0.052) and higher frequency of central
nervous system (CNS) anomalies (71.4% versus 28.6%, p= 0.076),
although the difference did not reach statistical significance.
Overall, individuals with PTVs have a more severe phenotype, and
the phenotypes of patients with PAVs was more variable. Of note,
the proportion of PTVs and PAVs was not significantly different
between male and female patients. Also, the phenotype variability
seen in patients with PAVs could perhaps be explained by allelic
heterogeneity, differences in the genetic background, or other
multifactorial effects. Although most pathogenic KDM6A PAVs
were located in known functional domains, the demethylase-
independent mechanism for some PAVs20 might also explain
these differences. It must be noted that we have not collected
scores of formal developmental and neuropsychological assess-
ments. In future, systematic studies could provide more objective
assessments in these domains.
Congenital and sensory anomalies in patients with pathogenic
KDM6A variants
Cardiovascular anomalies were reported in 49.2% of patients of
our cohort who underwent echocardiogram (Table 1 and
Supplementary Table S1). This appears to be higher than the
reported frequency of 37–42% in cases of KS.29,30 The commonest
congenital heart defect was atrial septal defect, followed by
ventricular septal defect. Aortic anomalies such as coarctation,
bicuspid valve, and stenosis were also frequent. One individual,
who was 11 years old, was also reported to have aortic dilatation.
The prevalence of genitourinary anomalies (e.g., kidney and
urinary tract malformations, hypercalciuria, abnormal genitalia)
was also higher in our cohort (26.4%) (Table 1 and Supplementary




















































































































































































Fig. 3 Sex and variant type differences in type 2 Kabuki syndrome. The upper panel shows the comparison of frequency of selected
phenotypes between males and females with either PTVs or PAVs. Clinical features are arranged alphabetically from left to right. The lower
panel shows the comparison of anthropometric data of patients at birth and at last examination. The y-axis denotes SD. Horizontal red lines
depict +2 SD and −2 SD. Groups for which we had sparse data (female PAV birth weight and HC) have not been shown in these charts. CNS
central nervous system, HC head circumference, PAV protein-altering variants (e.g., missense, in-frame indels), PTV protein-truncating variants
(e.g., nonsense, frameshift, splice site).
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Table S1) than what has been previously reported in KS. However,
the frequency of kidney/renal tract malformations was lower in
our study (only in 11.3% of patients) when compared with
previous reports (20–38%).14,30,31 The most frequent renal
malformation observed in our cohort is horseshoe kidneys.
The frequencies of palate and dental anomalies were high in
our cohort (64.2% and 60%, respectively) (Table 1 and Supple-
mentary Table S1), but the presence of cleft lip/palate and
hypodontia was lower (11.9% and 22.2%, respectively) when
compared with previous reports (35–50% and 48–85%, respec-
tively).29–31,34
Around one third (31.3%) of patients in our cohort have
strabismus, which has been reported in 21–36% of patients of
with KS.29,30,35 Interestingly, around 11% of patients in our cohort
reported nystagmus. The basis of nystagmus in KS2 patients is
unclear and needs further investigation. One individual was
reported to have microphthalmia and chorioretinal coloboma,
which has also been previously described for KMT2D.36
Hearing loss affected 30.8% of individuals of our cohort, similar
to the 27–43% of reported patients with KS.30,31 Information on
type of deafness was not available for many patients and,
therefore, we did not perform any subgroup analysis.
The frequencies of anomalies depicted here must be inter-
preted with caution because of the differences in the levels of
available clinical details from different centers. To calculate the
frequencies of individual features, we removed the patients for
whom unequivocal data for presence or absence of that particular
feature were unavailable (e.g., patients who had not undergone
echocardiogram were not used to calculate the frequency of
congenital heart defects in the cohort). This may erroneously
inflate the frequency of some clinical features in our cohort
(presuming that when not investigated, absence of feature is
more likely than its presence). However, broadly these figures are
still likely to be useful indicators and will facilitate appropriate
management and surveillance of patients with pathogenic KDM6A
variants. These observations also emphasize the important role of
KDM6A in embryonic development.
Other systemic problems in patients with pathogenic KDM6A
variants
Endocrine abnormalities were seen in 38.3% of patients with
pathogenic KDM6A. Specifically, we detected a lower frequency of
premature thelarche (6.4%) when compared with previous studies
(25–43%).30,31,37 A higher prevalence of neonatal hypoglycemic
(56.4% of the overall cohort) and hyperinsulinism (27.7%) were
detected in our cohort. Only 7% of KS cases show transient/
persistent hypoglycemia.30,37 The higher prevalence of hypogly-
cemia and hyperinsulinism in KS2 has been suspected
previously.6,8,17 Notably, inhibition of KDM6A increases the release
of insulin from mouse pancreatic islets.38
Recurrent infections were reported in 42.3% of patients in our
cohort, similar to 48–69% of patients with KS of previous
studies.29,31,37 We did not collect data about specific immune
profiles, types and severity of infections, or responses to
treatments. These need to be studied in more detail in the future.
Of note, one patient was reported to have vitiligo and one to have
hypothyroidism. Notably, various autoimmune features have been
reported in patients with KS1.13 Gastrointestinal problems,
especially feeding difficulties (requiring use of nasogastric tube
or gastrostomy), were reported in 61.1% of patients of our cohort.
Gastrointestinal problems have been described in 29–74% of
patients with clinically diagnosed KS.31,37 Males have higher
frequency of gastrointestinal problems.
Brachy/clinodactyly and joint hypermobility were the most
prevalent musculoskeletal anomalies, which were described in
80% of patients of our cohort, which is similar to ~88% of reported
patients with KS.29–31 No cases of multiple joint dislocations were
recorded in our study. Ectodermal abnormalities such as persistent
fingertip pads were detected in 72.9% of patients in our work,
which have been described in 82–92% of reported patients with
KS.29–31,39
Facial dysmorphism in patients with pathogenic KDM6A variants
Facial dysmorphism is considered to be the most distinguishing
feature of KS1.40 However, only 63.7% of patients in our cohort
had typical facial features of KS (Fig. 2). There was no obvious
association or pattern of presence of typical facial features and the
sex of the patient or the type of variant. However, some
individuals with PAVs in TPR regions may have less typical facial
dysmorphism (see individuals 15, 16, 17, and 20 in Fig. 2). These
observations suggest that atypical facial dysmorphism, on its own,
may be insufficient to rule out pathogenicity of a VUS in KDM6A.
Conclusion
This study substantially extends the spectrum of pathogenic
KDM6A variants and delineates the clinical phenotype of KS2. We
demonstrate that males and patients with PTVs tend to be more
severely affected. We show the overlaps and differences between
the phenotypes of KS2 and KS1. These findings will impact on
diagnosis, counseling, monitoring, and treatment of patients with
KS2. They also highlight areas of future clinical research need in
KS2 and will lead to evidence-based clinical management
guidelines for patients.
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